STOCK TITAN

Iridex - IRIX STOCK NEWS

Welcome to our dedicated page for Iridex news (Ticker: IRIX), a resource for investors and traders seeking the latest updates and insights on Iridex stock.

Iridex Corporation (IRIX) delivers innovative laser-based medical systems for ophthalmology, specializing in noninvasive treatments for glaucoma and retinal diseases. This news hub provides investors and healthcare professionals with timely updates on product developments, financial performance, and clinical advancements.

Access authoritative information about IRIX's proprietary MicroPulse technology, regulatory milestones, and global market initiatives. Our curated collection features earnings announcements, partnership updates, and clinical study results – all essential for tracking the company's position in medical device innovation.

Discover updates across key categories including new product clearances, international distribution expansions, and peer-reviewed research findings. Content is regularly updated to reflect IRIX's progress in enhancing ophthalmic care through advanced laser systems and procedural tools.

Bookmark this page for streamlined access to verified Iridex developments. Combine strategic business insights with technical expertise through our comprehensive news repository – your primary source for monitoring this medical technology leader's trajectory.

Rhea-AI Summary

Iridex Corporation (NASDAQ: IRIX) announced it will release its financial results for Q4 and full year 2021 on March 10, 2022, after market close. A conference call will follow at 2:00 p.m. PT / 5:00 p.m. ET, accessible by dialing (844) 707-0665 for domestic callers or (703) 326-3030 internationally, using conference ID: 1574126. Iridex specializes in innovative ophthalmic laser-based products, particularly for glaucoma and retinal diseases, leveraging its proprietary MicroPulse® technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
conferences earnings
-
Rhea-AI Summary

Iridex Corporation (Nasdaq: IRIX) announced strong preliminary results for Q4 2021 and full year 2021, exceeding prior guidance. Q4 revenue is expected to be between $15.1 million and $15.3 million, a 24% increase year-over-year. The full year revenue is projected at $53.7 million to $53.9 million, marking nearly 50% growth from 2020. The company sold 15,200 Cyclo G6® probes in Q4, a 13% increase, and 90 Glaucoma Laser Systems, up from 57 a year prior. Cash and cash equivalents stand at $23.8 million as of January 1, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.63%
Tags
-
Rhea-AI Summary

Iridex Corporation (Nasdaq: IRIX) announced participation in the 2021 Stifel Virtual Healthcare Conference, scheduled for November 16, 2021, at 2:00 pm ET. David Bruce, President and CEO, will present, and interested parties can access the live and archived webcast at www.iridex.com. Iridex specializes in ophthalmic laser-based medical products targeting glaucoma and retinal diseases, utilizing proprietary MicroPulse technology for effective treatments. Their products are distributed in over 100 countries, enhancing patient care globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.67%
Tags
conferences
Rhea-AI Summary

Iridex Corporation (Nasdaq: IRIX) reported a robust 51% year-over-year revenue growth for Q3 2021, reaching $13.3 million. The gross margin improved to 43.6%, aided by production efficiencies. Despite the positive revenue results, the company experienced a net loss of $2.2 million, which increased compared to the previous year. The revenue guidance for 2021 has been raised to $52 million-$53 million, reflecting a 43%-46% growth, though expectations for Glaucoma Laser System sales have been adjusted downwards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.67%
Tags
-
Rhea-AI Summary

On November 6, 2021, Iridex Corporation (NASDAQ: IRIX) will host an international expert consensus panel discussing MicroPulse Transscleral Laser Therapy (TLT). The panel aims to provide insights on dosing and patient selection for better treatment outcomes. Key points include fluence, sweep speed, and drivers for patient selection. This event aligns with the upcoming American Academy of Ophthalmology meeting from November 13-15, where Iridex will showcase its innovations and host experts for discussions on the effectiveness of laser therapies for glaucoma and retinal diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Iridex Corporation (NASDAQ: IRIX) will announce its Q3 2021 financial results after market close on November 11, 2021. The management team will conduct a conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results. Interested investors can join the call by dialing (844) 707-0665 domestically or (703) 326-3030 internationally, using conference ID: 7496524. An archived webcast will be accessible on the Investors section of the company's website thereafter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
conferences earnings
Rhea-AI Summary

Iridex Corporation (Nasdaq: IRIX) announced its participation in the Lytham Partners Fall 2021 Investor Conference, scheduled for October 7, 2021, at 11:45 am ET. David Bruce, President and CEO, will present at the conference. A live and archived webcast will be available on the company's website. Iridex specializes in developing innovative ophthalmic laser-based medical products for conditions like glaucoma and retinal diseases, leveraging its proprietary MicroPulse technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
conferences
-
Rhea-AI Summary

Iridex Corporation (Nasdaq: IRIX) reported a remarkable 116% year-over-year revenue growth for Q2 2021, reaching $13.4 million, the highest since 2007. Gross profit also soared to $6.1 million with a 45.5% gross margin. The company achieved record sales of Cyclo G6 probes, totaling 16,000 units, a 103% increase from last year. Net income turned positive at $1.4 million, compared to a net loss of $2.8 million a year ago. Iridex updated its full year 2021 revenue guidance to $50 million - $52 million, indicating a growth of 38% - 43% compared to 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.91%
Tags
-
Rhea-AI Summary

IRIDEX Corporation (Nasdaq: IRIX) has announced its participation in the upcoming H.C. Wainwright Ophthalmology Virtual Conference set for August 17, 2021. The company specializes in innovative ophthalmic laser-based medical products aimed at treating conditions such as glaucoma and retinal diseases. David Bruce, the President and CEO, is scheduled to present at 7:00 am ET. Interested parties can access the live and archived webcast through iridex.com.

The company is recognized for its MicroPulse® technology, enhancing treatments for eye conditions worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
conferences
Rhea-AI Summary

Iridex Corporation (NASDAQ: IRIX), based in Mountain View, California, plans to release its financial results for Q2 2021 on August 12, 2021, after market close. The management team will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results. Investors can join the call by dialing (844) 707-0665 domestically or (703) 326-3030 internationally, using conference ID: 9257308. A live and archived webcast will also be available on Iridex's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
conferences earnings
Iridex

Nasdaq:IRIX

IRIX Rankings

IRIX Stock Data

16.97M
13.34M
20.67%
19.45%
1.6%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
MOUNTAIN VIEW